HopeStage
Back to all studies
CompletedNCT04786730

Safety and drug levels of centanafadine in children with ADHD

About this title

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Read the official source — NCT04786730

This study evaluated the safety of Centanafadine for people with ADHD.

Medication studyAges 4–12United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of Centanafadine for people with ADHD.

Who was this study for?

Listed age limits: 4 years to 12 years.

Listed locations
Little Rock and 4 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateStarted: March 9, 2021
Recruitment status
Completed
Enrollment listed in the registry
50
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 4 Years to 12 Years
Official registry ID
NCT04786730
Official title
Show the full official title

A Phase 1b, Multicenter, Open-label, Multiple Ascending Dose Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (4 to 12 Years, Inclusive) With Attention-deficit Hyperactivity Disorder

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Little Rock · Decatur · Las Vegas

2 more locations
  • Oklahoma City
  • San Antonio
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of Centanafadine for people with ADHD.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Centanafadine.

Who was this study for?

Listed age limits: 4 years to 12 years.

Want to explore more studies?

Explore studies